PrognosDx Health Announces Publication of Novel Epigenetic Study in Journal of Clinical Oncology

Published: Feb 10, 2010

Bookmark and Share

PALO ALTO, Calif.--(BUSINESS WIRE)--PrognosDx Health, Inc. announced today that in an independent research study published online in the Journal of Clinical Oncology, cellular levels of histone modifications define previously unrecognized subsets of patients with pancreatic cancer with distinct epigenetic phenotypes and clinical outcomes. Histone modifications represent novel prognostic and predictive biomarkers that could inform clinical decisions, including use of fluorouracil (5-FU) chemotherapy.

Back to news